HNWAG
INMB icon

High Net Worth Advisory Group’s INmune Bio INMB Stock Holding History

High Net Worth Advisory Group’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500
Closed -$4K – 701
2022
Q2 		$4K Hold
500
– – ﹤0.01% 599
2022
Q1 		$4K Hold
500
– – ﹤0.01% 602
2021
Q4 		$5K Buy
+500
New +$7.4K ﹤0.01% 599

Other funds holding INMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

High Net Worth Advisory Group's INMB Position: Q3 2022 in Review

High Net Worth Advisory Group sold out of INmune Bio (INMB) in Q3 2022, closing a stake of 500 shares — an estimated $4K sold.

High Net Worth Advisory Group first reported a position in INMB in Q4 2021 and held it in 3 quarters. The position peaked at $5K in Q4 2021. 33 funds tracked by Wall St. Rank hold INMB as of Q3 2022.

  • High Net Worth Advisory Group reported no remaining INmune Bio position as of Q3 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 500 INmune Bio shares in Q3 2022, an estimated $4K.
  • High Net Worth Advisory Group first reported a position in INmune Bio in Q4 2021 and held it in 3 quarters.
  • High Net Worth Advisory Group's INmune Bio position peaked at $5K in Q4 2021.
  • 33 funds tracked by Wall St. Rank held INmune Bio as of Q3 2022.

Based on High Net Worth Advisory Group's 13F filing for Q3 2022, filed 24 Oct 2022.